ClinicalTrials.gg
CompletedNCT01748175SARPIIIUpdated Sep 16, 2022

Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma

An observational study in Asthma and Severe Persistent Asthma, sponsored by Sally E. Wenzel MD. Completed at 1 site in United States. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by Sally E. Wenzel MD · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
715
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.

Enrollment
59th of 330
715 · median 112
Started
2013
with 80 others
Observational
335 of 1,696
34 open now
Registered
800th of 1,696
by date

Among the 1,696 studies in Asthma with a site in United States, this one is the 59th largest by enrollment of the 330 observational ones that give a count, is one of 81 that started in 2013, is one of 335 observational ones, and was the 800th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 6 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,696 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The Severe Asthma Research Program III is an NIH cooperative agreement involving 7 clinical centers that encompass a multidisciplinary partnerships between asthma clinician-scientists and scientists with expertise in immunology, pulmonary physiology, molecular genetics, molecular phenotyping, imaging, and bioinformatics. These clinical centers will jointly recruit volunteers with asthma for an observational longitudinal follow-up study. However, centers will also conduct specific mechanistic research projects at each participating institution. The University of Pittsburgh's SARP III study will determine the molecular and clinical stability of asthma phenotypes over time.

Read the detailed description

The longitudinal follow-up study is divided into a characterization and longitudinal phase. During the characterization subjects will undergo a baseline evaluation that will include will include answering questionnaires, lung function testing, and chest tomography. Subsequently, to determine steroid responsiveness, all subjects will receive one intramuscular dose of 40 mg in 1ml (1 mg/kg for children \<18 years old, up to 40 mg maximum. Participants at the University of Pittsburgh will undergo a bronchoscopy to provide airway samples. The longitudinal phase will include a 36 month follow-up time with annual visits and phone calls every 6 months. During it, participants will answer questionnaires and provide sputum samples on two occasions, and will perform lung function testing.

The SARP III longitudinal follow up study (all centers) will determine the long term stability and implications of clinical and molecular asthma phenotypes and identify potential systemic biomarkers for these phenotypes

The University of Pittsburgh center will test the hypothesis that a) a mast cell signature is present and longitudinally maintained in severe asthma; and b) That the persistent signature determines short and long term outcomes through interactions with lung and inflammatory cells.

03

Conditions studied

  • Asthma
  • Severe Persistent Asthma

Browse trials for

Keywords

  • Severe asthma
  • longitudinal study
  • phenotypes
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with asthma meeting inclusion and exclusion criteria will be recruited from 7 SARP III participating clinical centers. The clinical centers are located at Brigham and Women's Hospital (with co-investigators at Children's Hospital), the University of California San Francisco, the University of Pittsburgh, the University of Virginia (with co-investigators at the Cleveland Clinic, Case Western Reserve and Virginia Commonwealth University), the University of Wisconsin, Wake Forest School of Medicine (with co-investigators at Emory University), and Washington University in St. Louis (with co-investigators at the University of Iowa).

Eligibility criteria

Asthmatic Subjects

Inclusion Criteria:

  • Previous asthma diagnosis
  • bronchodilator reversibility ≥12% or airway hyperresponsiveness reflected by a methacholine PC20 ≤16 mg/mL (Historical methacholine data from previous NIH trial [SARP I or II, AsthmaNet, ALA-ACRC, ACRN or CARE] will be allowed).

Exclusion Criteria:

  • Exclusion criteria include any of the following:
  • Pregnancy during the characterization phase
  • Current smoking,
  • Smoking history > 10 pack years if ≥30 years of age, or smoking history > 5 pack years if \<30 years of age (Note: if a subject has a smoking history, no smoking within the past year),
  • Other chronic pulmonary disorders associated with asthma-like symptoms, including (but not limited to) cystic fibrosis, , chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways,
  • History of premature birth before 35 weeks gestation,
  • Unwillingness to receive an intramuscular triamcinolone acetonide injection.
  • Evidence that the participant or family may be unreliable or poorly adherent to their asthma treatment or study procedures,
  • Planning to relocate from the clinical center area before study completion,
  • Any other criteria that place the subject at unnecessary risk according to the judgment of the Principal Investigator and/or attending physician(s) of record, or
  • Currently participating in an drug trial.

Healthy Controls:

Inclusion Criteria

  • Healthy subjects between the age of 18 and 65
  • At least 3 of the 7 subjects per center should be aged 35 or older

Exclusion Criteria:

  • History of chronic diseases that affect the lungs: Chronic airway disease (asthma, cystic fibrosis, COPD, chronic bronchitis, bronchiectasis); Interstitial lung disease, sarcoidosis, occupational lung disease; Obstructive sleep apnea; Vocal cord dysfunction; Severe scoliosis or chest wall deformities.
  • A history suggestive of allergic rhinitis (based on the best judgment of the physician investigator).
  • A history of eczema.
  • Chronic sinusitis.
  • An improvement in FEV1 of more than 12% following 4 puffs of albuterol.
  • Chronic systemic diseases requiring ongoing anti-inflammatory treatment.
  • Current use of beta adrenergic blocking agent or a cholinesterase inhibitor (medicine used to treat myasthenia gravis or Alzheimer's disease).
  • Smoking history > 10 pack years if ≥30 years of age, or smoking history > 5 pack years if \<30 years of age (Note: if a subject has a smoking history, no smoking within the past year).
  • Respiratory tract infection within the past 4 weeks.
  • Pregnancy.
  • History of premature birth (\<35 weeks).
  • Any other criteria that place the subject at increased risk of complications from study procedures, according to the judgment of the Principal Investigator and/or attending physician(s) of record.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
715 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Longitudinal follow up

    Patients will undergo a characterization phase, which includes a baseline evaluation (1 visit), and a steroid responsiveness evaluation (2 visits). The longitudinal phase will include 3 office visits (annually) over 36 months with bi-annual phone calls. During the study patients will answer questionnaires, perform lung function testing and provide blood, urine, sputum and exhaled breath condensate samples.

    Drug: Triamcinolone Acetonide

Interventions

  • Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region

    Also known as: Kenalog

06

What researchers measure

Primary outcomes

  1. Airway lumen mast cells

    Determine the impact of mast cell markers on human airway epithelial cell phenotype and function.

    Time frame: Once, during bronchoscopy

  2. Longitudinal asthma phenotype

    Determine the long term stability and implications of previously identified clinical and molecular asthma phenotypes, specifically the mast cell signature, and identify potential systemic biomarkers for these phenotypes. Determine whether a biomarker for the lung mast cell signature can be identified in serum/plasma of both adult and pediatric severe asthmatics

    Time frame: Change rates, determined annually for three years

07

Study locations

1 site
  • Asthma Institute, UNiversity of Pittsburgh and University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Publications

  • DeBoer MD, Phillips BR, Mauger DT, Zein J, Erzurum SC, Fitzpatrick AM, Gaston BM, Myers R, Ross KR, Chmiel J, Lee MJ, Fahy JV, Peters M, Ly NP, Wenzel SE, Fajt ML, Holguin F, Moore WC, Peters SP, Meyers D, Bleecker ER, Castro M, Coverstone AM, Bacharier LB, Jarjour NN, Sorkness RL, Ramratnam S, Irani AM, Israel E, Levy B, Phipatanakul W, Gaffin JM, Gerald Teague W. Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma. BMC Pulm Med. 2018 Apr 10;18(1):58. doi: 10.1186/s12890-018-0612-x. PubMed 29631584 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Dec 2021 and a completion of Jan 2022. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2012
First posted
Dec 12, 2012
Start
Jan 2013
Primary completionActual
Dec 2021
CompletionActual
Jan 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01748175
Lead sponsor
Sally E. Wenzel MD
Responsible party
Sally E. Wenzel MD (Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Dec 12, 2012
Start date
Jan 2013
Primary completion
Dec 2021
Completion
Jan 2022
Last update
Sep 16, 2022

Study contacts

Sally E Wenzel, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion